Dermot Kenny, who leads STEM and Research Partnership within Inizio Advisory, shares his journey from bench scientist to CEO, ...
The clinical research environment has undergone considerable transformation over the past decade. Protocols are more complex, product pipelines increasingly target smaller and more distributed patient ...
The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...
BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, ...
Daiichi Sankyo and AstraZeneca have pressed swiftly to file for approval of their TROP2-targeting drug Datroway for ...
The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership, is providing up to $54.3 million in ...
In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...
At Frontiers Health 2025, Mike Ryan, General Manager Europe at EVERSANA, tackled one of the most pressing questions for ...
Our roundup of financings in the biotech arena this week is led by a $125 million Series A for Ambros Therapeutics, a startup ...
The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...
The ECDC warns of a ‘perfect storm’ and calls for innovation, including through the development of new medicines, enhanced ...
Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback